Scandinavian ChemoTech AB Class B (SE:CMOTEC.B)
:CMOTEC.B
Top Page
Scandinavian ChemoTech AB Class B
(CMOTEC.B)
Select Model
Select Model
Rating:45Neutral
Price Target:
kr4.00
▼(-16.49% Downside)
Action:ReiteratedDate:01/20/26
The score is held back primarily by heavy ongoing losses, negative free cash flow, and erosion of equity despite improving revenue growth and gross margins. Technical indicators also remain weak with the stock trading below key moving averages and negative MACD, while valuation is difficult to support with a negative P/E and no dividend yield provided.
Positive Factors
Recurring consumables revenue model
ChemoTech’s business model generates recurring revenue from single-use consumables and procedure items tied to installed IQwave systems. As installed base grows, recurring consumable sales create a durable, high-frequency revenue stream that can stabilize cash flows and margin profiles over time.
Negative Factors
Persistent negative free cash flow
Large negative free cash flow (~-13.1M in 2024) shows the company is burning cash despite revenue gains. Over the medium term this creates dependence on external financing, increases execution risk, and may force tradeoffs between growth investments and capital preservation if cash burn does not decline.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables revenue model
ChemoTech’s business model generates recurring revenue from single-use consumables and procedure items tied to installed IQwave systems. As installed base grows, recurring consumable sales create a durable, high-frequency revenue stream that can stabilize cash flows and margin profiles over time.
Read all positive factors
Scandinavian ChemoTech AB Class B (CMOTEC.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr95.20M
Dividend YieldN/A
Average Volume (3M)54.14K
Price to Earnings (P/E)―
Beta (1Y)-0.59
Revenue Growth132.07%
EPS Growth54.65%
CountrySE
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.10
Shares Outstanding23,802,313
10 Day Avg. Volume61,695
30 Day Avg. Volume54,140
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)6.99
Price to Sales (P/S)6.36
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr21.20M
Scandinavian ChemoTech AB Class B Business Overview & Revenue Model
Company Description
Scandinavian ChemoTech AB (publ) provides cancer care and pain management solutions. Its product, IQWave, is an electroporation device, which combines short electric pulses with chemotherapy administrated locally or intravenously used for treating...
How the Company Makes Money
Scandinavian ChemoTech AB generates revenue primarily through the sale and licensing of its proprietary medical technologies and devices designed for cancer treatment. The company's revenue streams include direct sales of its electroporation equip...
Scandinavian ChemoTech AB Class B Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
44
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.85M | 6.57M | 2.82M | 473.00K | 49.00K | 131.00K |
| Gross Profit | 7.69M | 4.78M | 1.66M | -55.00K | 323.00K | -14.00K |
| EBITDA | -7.46M | -12.38M | -19.58M | -20.81M | -17.03M | -10.77M |
| Net Income | -10.68M | -13.72M | -21.09M | -22.75M | -17.74M | -11.66M |
Balance Sheet | ||||||
| Total Assets | 12.48M | 13.38M | 14.87M | 21.70M | 25.81M | 15.99M |
| Cash, Cash Equivalents and Short-Term Investments | 517.00K | 949.00K | 923.00K | 5.85M | 8.68M | 1.49M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 53.00K | 2.71M |
| Total Liabilities | 10.29M | 7.40M | 3.84M | 7.71M | 1.89M | 6.75M |
| Stockholders Equity | 2.19M | 5.98M | 11.03M | 13.99M | 23.92M | 9.24M |
Cash Flow | ||||||
| Free Cash Flow | -9.48M | -13.19M | -18.91M | -19.96M | -22.36M | -10.32M |
| Operating Cash Flow | -9.48M | -13.14M | -18.23M | -19.63M | -19.18M | -8.49M |
| Investing Cash Flow | 52.00K | -2.00K | -468.00K | -603.00K | -3.33M | -1.83M |
| Financing Cash Flow | 8.09M | 13.17M | 13.77M | 17.26M | 29.71M | 8.98M |
Scandinavian ChemoTech AB Class B Technical Analysis
Neutral
4.79
Price Trends
3.70
Positive
4.07
Negative
3.82
Negative
Market Momentum
0.04
Negative
52.13
Neutral
81.17
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CMOTEC.B, the sentiment is Neutral. The current price of 4.79 is above the 20-day moving average (MA) of 3.54, above the 50-day MA of 3.70, and above the 200-day MA of 3.82, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 52.13 is Neutral, neither overbought nor oversold. The STOCH value of 81.17 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:CMOTEC.B.
Scandinavian ChemoTech AB Class B Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | kr215.25M | 1.48 | -264.12% | ― | -17.80% | -11.96% | |
54 Neutral | kr27.36M | -4.94 | -30.39% | 11.26% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | kr79.37M | -5.14 | -202.18% | ― | ― | 20.55% | |
45 Neutral | kr95.20M | -14.97 | -211.04% | ― | 132.07% | 54.65% | |
44 Neutral | kr15.23M | -1.19 | -88.65% | ― | 8.46% | 11.73% | |
43 Neutral | kr46.14M | -1.97 | ― | 8.47% | -94.12% | -25.83% |
* Healthcare Sector Average
SE:CMOTEC.B
Scandinavian ChemoTech AB Class B
3.61
2.45
211.21%
SE:2CUREX
2cureX AB
1.09
0.73
204.47%
SE:ONCOZ
OncoZenge AB
5.79
-0.28
-4.61%
SE:EXPRS2
ExpreS2ion Biotech Holding AB
4.20
-17.21
-80.40%
SE:LARK
CombiGene AB
2.15
-0.06
-2.63%
SE:SPRINT
Sprint Bioscience AB
1.98
1.28
183.36%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.